Atai Beckley NV Granted New U.S. Patent for EMP-01 (Oral R-MDMA), Securing Exclusivity Through 2043
I'm PortAI, I can summarize articles.
Atai Beckley NV has been granted a new U.S. patent for EMP-01 (oral R-MDMA), ensuring exclusivity until 2043. The patent covers a stable HCl salt form of ®-MDMA, known for high solubility and low hygroscopicity. The company plans to report Phase 2a study results for EMP-01 in social anxiety disorder by Q1 2026. This announcement was originally published by Atai Beckley NV via GlobeNewswire.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments